

Notice: This is a translation of a notice in Japanese and is made solely for the convenience of foreign shareholders.

In the case of any discrepancy between the translation and the Japanese original, the latter shall prevail.

(Translation)

May 9, 2024

To Shareholders,

Company Name: Renascience Inc.

Name of Representative: Koji Naito, President & CEO

(Code: 4889 TSE Growth)

For inquiries, please contact: Administration Dept.

Notice of Difference between Financial Forecast and Actual Results

The Company announces the following difference between its full-year earnings forecast for the fiscal year ending March 31, 2024 (April 1, 2023, to March 31, 2024), which was announced on May 11, 2023, and the actual results announced today.

record

- 1 Difference between the forecast and actual results for the fiscal year ending March 31, 2024 (April 1, 2023 - March 31, 2024)

	Operating revenue	Operating profit	Ordinary income	Net income for the year	Net income per share
Forecast (A)	Million yen 248	Million yen △243	Million yen △243	Million yen △244	Yen △19.26
Actual value (B)	194	△252	△251	△258	△20.32
Increase (Decrease) (B-A)	△54	△9	△8	△13	
Increase (Decrease) (%)	△21.9	-	-	-	
(Reference) Results for the previous period (Fiscal year ending March 31, 2023)	100	△333	△333	△ 335	△26.42

- 2 Reasons for the differences

As stated in the "Notice of Conclusion of Collaboration Agreement with Nipro Corporation" announced on March 14, 2024, the Company concluded a joint development agreement with Nipro Corporation and planned to record an upfront payment of 30 million yen as revenue for the fourth quarter of the fiscal year ending March 31, 2024. However, after discussions with the auditor, the Company decided to record the revenue in the first quarter of the fiscal year ending March 31, 2025. The Company have confirmed that the payment was received in April 2024.

Operating profit fell 9 million yen from the initial forecast due to the compensation paid to outside parties and reductions of the expenses in selling, general and administrative expenses.

End